Zidovudine (Synonyms: Azidothymidine; AZT; ZDV)

Name: Zidovudine
Brand: MedChemExpress
SKU: HY-17413
Rating: 5.0 (6 reviews)

Cat. No.: HY-17413 Purity: 99.95%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.

For research use only. We do not sell to patients.

Zidovudine Chemical Structure

CAS No. : 30516-87-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 87	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 87	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 79	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 172	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Zidovudine:

6 Publications Citing Use of MCE Zidovudine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.

IC₅₀ & Target^[1]^[2]

HIV-1

CRISPR/Cas9

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	12.25 μM Compound: AZT, Zidovudine	Cytotoxicity against human 143B cells after 72 hrs by MTT assay Cytotoxicity against human 143B cells after 72 hrs by MTT assay	[PMID: 25440502]
143B	IC₅₀	148.42 μM Compound: AZT, Zidovudine	Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay	[PMID: 25440502]
5637	IC₅₀	128.82 μM Compound: AZT	Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 30108758]
5637	IC₅₀	7 μM Compound: 1	Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25811955]
A549	IC₅₀	0.011 μM Compound: AZT	Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry	[PMID: 19537689]
A549	IC₅₀	0.012 μM Compound: AZT	Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry	[PMID: 19537689]
A549	IC₅₀	11.86 μM Compound: 3; AZT	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
A549	IC₅₀	16.19 μM Compound: 13, AZT	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 25933593]
AA5	IC₅₀	< 0.0003 μM Compound: AZT	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	> 0.1 μM Compound: AZT	Cytotoxicity against human AA5 cells by MTS assay Cytotoxicity against human AA5 cells by MTS assay	[PMID: 20086149]
AA5	IC₅₀	0.0003 μM Compound: AZT	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	0.0004 μM Compound: AZT	Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
AA5	IC₅₀	0.006 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	0.008 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
AA5	IC₅₀	0.009 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
B(EBV+)	EC₅₀	0.001 μM Compound: AZT	Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay	[PMID: 7932526]
Bel-7402	EC₅₀	4.62 μM Compound: Zidovudine	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 18313175]
Bone marrow cell	CC₅₀	0.5 μM Compound: ZDV, AZT	Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay	[PMID: 20439609]
Bone marrow cell	CC₅₀	0.89 μM Compound: ZDV, AZT	Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay	[PMID: 20439609]
BxT	EC₅₀	0.055 μM Compound: AZT	Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay	[PMID: 7932526]
C3H/3T3	EC₅₀	0.02 μM Compound: AZT	Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%. Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.	[PMID: 2016718]
C8166	CC₅₀	> 1 μM Compound: AZT	Cytotoxicity against C8166 cells by MTT assay Cytotoxicity against C8166 cells by MTT assay	[PMID: 16279773]
C8166	CC₅₀	> 100 μg/mL Compound: AZT	Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay	[PMID: 19515569]
C8166	CC₅₀	> 1000 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 19413342]
C8166	CC₅₀	> 1000 μM Compound: 1	Concentration which reduces the viability of uninfected C8166 cells by 50% Concentration which reduces the viability of uninfected C8166 cells by 50%	10.1016/0960-894X(96)00446-5
C8166	CC₅₀	> 1000 μM Compound: AZT	Concentration of compound required to reduce viability of C8166 cells by 50%. Concentration of compound required to reduce viability of C8166 cells by 50%.	10.1016/0960-894X(96)00444-1
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay	[PMID: 23368966]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against C8166 cells after 72 hrs by MTT method Cytotoxicity against C8166 cells after 72 hrs by MTT method	[PMID: 17489633]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 23327759]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 23078294]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 20146529]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT method Cytotoxicity against human C8166 cells by MTT method	[PMID: 18088099]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT method Cytotoxicity against human C8166 cells by MTT method	[PMID: 16643044]
C8166	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 16499331]
C8166	CC₅₀	> 200 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23738539]
C8166	CC₅₀	> 749 μM Compound: AZT, zidovudine	Cytotoxicity against human C8166 cells after 72 hrs by MTT method Cytotoxicity against human C8166 cells after 72 hrs by MTT method	[PMID: 18316190]
C8166	EC₅₀	0.00152 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method	[PMID: 27039251]
C8166	EC₅₀	0.0019 μM Compound: AZT	Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay	[PMID: 19170521]
C8166	EC₅₀	0.0034 μg/mL Compound: AZT	Antiviral activity against HIV1 in C8166 cells after 72 hrs Antiviral activity against HIV1 in C8166 cells after 72 hrs	[PMID: 18088099]
C8166	IC₅₀	0.004 μM Compound: AZT	Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain	10.1016/0960-894X(95)00257-T
C8166	EC₅₀	0.00436 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method	[PMID: 27039251]
C8166	EC₅₀	0.00794 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy	[PMID: 27039251]
C8166	EC₅₀	0.00812 μM Compound: AZT	Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction	[PMID: 21689939]
C8166	EC₅₀	0.0087 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy	[PMID: 23046280]
C8166	EC₅₀	0.0108 μM Compound: AZT	Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay	[PMID: 18396905]
C8166	EC₅₀	0.011 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay	[PMID: 18316190]
C8166	EC₅₀	0.0128 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay	[PMID: 21788138]
C8166	EC₅₀	0.013 μM Compound: Zidovudine	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method	[PMID: 27894873]
C8166	EC₅₀	0.016 μg/mL Compound: AZT	Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA	[PMID: 11374977]
C8166	EC₅₀	0.016 μM Compound: AZT	Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA	10.1016/S0960-894X(97)00022-X
C8166	EC₅₀	0.017 μM Compound: AZT	Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days	[PMID: 17291043]
C8166	EC₅₀	0.019 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days	[PMID: 23099098]
C8166	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay	[PMID: 24299567]
C8166	EC₅₀	0.0228 μM Compound: AZT	Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 23164656]
C8166	EC₅₀	0.023 μM Compound: AZT	Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay	[PMID: 21788138]
C8166	EC₅₀	0.023 μM Compound: AZT	Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope	[PMID: 21719299]
C8166	EC₅₀	0.03 μM Compound: AZT	Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells	10.1016/0960-894X(95)00208-B
C8166	EC₅₀	0.034 μg/mL Compound: AZT	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days	[PMID: 23368966]
C8166	EC₅₀	0.034 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay	[PMID: 23738539]
C8166	EC₅₀	0.1293 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 21689939]
C8166	EC₅₀	10.59 nM Compound: AZT	Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 21689939]
C8166	CC₅₀	1139.47 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 20488700]
C8166	CC₅₀	1145 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 20598530]
C8166	EC₅₀	12.8 nM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 23164656]
C8166	EC₅₀	12.82 nM Compound: AZT	Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope	[PMID: 21719299]
C8166	CC₅₀	200 μg/mL Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 19685905]
C8166	EC₅₀	39 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay	[PMID: 23164656]
C8166	EC₅₀	39 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope	[PMID: 21719299]
C8166	CC₅₀	3987.58 μM Compound: AZT	Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 34812640]
C8166	CC₅₀	4.07 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21650224]
C8166	CC₅₀	4.07 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21534540]
C8166	EC₅₀	4.5 nM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay	[PMID: 21561060]
C8166	CC₅₀	4071.9 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 21561060]
C8166	CC₅₀	4107.39 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23046280]
C8166	CC₅₀	4552.1 μM Compound: AZT	Cytotoxicity against C8166 cells by MTT method Cytotoxicity against C8166 cells by MTT method	[PMID: 17291043]
C8166	CC₅₀	4676.07 μM Compound: AZT; zidovudine	Cytotoxicity against human C8166 cells after 72 hrs by MTT assay Cytotoxicity against human C8166 cells after 72 hrs by MTT assay	[PMID: 27039251]
C8166	CC₅₀	4690 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 26214125]
C8166	CC₅₀	4913.8 μM Compound: AZT	Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay	[PMID: 23164656]
C8166	CC₅₀	5041 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days	[PMID: 21194939]
C8166	CC₅₀	5091 μM Compound: AZT	Cytotoxicity against human C8166 cells after 72 hrs by MTT assay Cytotoxicity against human C8166 cells after 72 hrs by MTT assay	[PMID: 18396905]
C8166	CC₅₀	5110 μM Compound: AZT	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23099098]
C8166	CC₅₀	5231.6 μM Compound: AZT	Cytotoxicity against human C8166 cells after 72 hrs by MTT assay Cytotoxicity against human C8166 cells after 72 hrs by MTT assay	[PMID: 30596489]
C8166	CC₅₀	5401.4 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21788138]
C8166	CC₅₀	5401.4 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT colorimetric assay Cytotoxicity against human C8166 cells by MTT colorimetric assay	[PMID: 21719299]
C8166	CC₅₀	5601.71 μM Compound: AZT	Cytotoxicity against human C8166 cells by MTT assay Cytotoxicity against human C8166 cells by MTT assay	[PMID: 21689939]
C8166	CC₅₀	5746.1 μM Compound: AZT	Cytotoxicity against C8166 cells by MTT assay Cytotoxicity against C8166 cells by MTT assay	[PMID: 17315963]
C8166	CC₅₀	5858.85 μM Compound: Zidovudine	Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay	[PMID: 27894873]
Caco-2	IC₅₀	0.006 mg/mL Compound: AZT	Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs	[PMID: 17337193]
Caco-2	IC₅₀	0.015 mg/mL Compound: AZT	Growth inhibition of human Caco-2 cells after 72 hrs Growth inhibition of human Caco-2 cells after 72 hrs	[PMID: 17079149]
Caco-2	IC₅₀	0.015 mg/mL Compound: AZT	Cytotoxicity against human Caco-2 cells after 72 hrs Cytotoxicity against human Caco-2 cells after 72 hrs	[PMID: 17079149]
Caco-2	IC₅₀	22.39 μM Compound: AZT	Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs	[PMID: 17555969]
Caco-2	IC₅₀	22.45 μM Compound: AZT	Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs	[PMID: 18037195]
Caco-2	IC₅₀	22.45 μM Compound: AZT	Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs	[PMID: 17337193]
Caco-2	CC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human Caco-2 cells after 72 hrs Cytotoxicity against human Caco-2 cells after 72 hrs	[PMID: 18037195]
Caco-2	CC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human Caco-2 cells after 72 hrs Cytotoxicity against human Caco-2 cells after 72 hrs	[PMID: 17548129]
Caco-2	IC₅₀	74.62 μM Compound: AZT	Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs	[PMID: 17555969]
Caco-2	IC₅₀	74.84 μM Compound: AZT	Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs	[PMID: 18037195]
CCRF-CEM	EC₅₀	< 0.001 μM Compound: AZT	Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells	[PMID: 11170632]
CCRF-CEM	CC₅₀	> 100 μg/mL Compound: AZT	Cytotoxic concentration which is required to reduce human CEM cell viability by 50%. Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.	[PMID: 9046339]
CCRF-CEM	IC₅₀	> 100 μM Compound: 27, L-AZT	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay	[PMID: 21700368]
CCRF-CEM	CC₅₀	> 100 μM Compound: 1b; AZT	Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days	[PMID: 32515595]
CCRF-CEM	EC₅₀	> 100 μM Compound: 3 (AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	CC₅₀	> 100 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells	[PMID: 12593658]
CCRF-CEM	EC₅₀	> 100 μM Compound: AZT	Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells	[PMID: 12593658]
CCRF-CEM	CC₅₀	> 125 μg/mL Compound: zidovudine	Cytotoxic concentration required to reduce CEM cell viability by 50% Cytotoxic concentration required to reduce CEM cell viability by 50%	[PMID: 8709116]
CCRF-CEM	CC₅₀	> 250 μM Compound: AZT	Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days	[PMID: 26125628]
CCRF-CEM	CC₅₀	> 250 μM Compound: AZT	Concentration of compound required to reduce viability of CEM/0 cells by 50%. Concentration of compound required to reduce viability of CEM/0 cells by 50%.	10.1016/0960-894X(96)00444-1
CCRF-CEM	CC₅₀	> 250 μM Compound: AZT	Concentration required to reduce cell viability of CEM/0 cells by 50% Concentration required to reduce cell viability of CEM/0 cells by 50%	10.1016/0960-894X(96)00443-X
CCRF-CEM	CC₅₀	> 500 μM Compound: AZT	Concentration required to reduce CEM/0 cell viability by 50% Concentration required to reduce CEM/0 cell viability by 50%	[PMID: 11356105]
CCRF-CEM	IC₅₀	0.003 μg/mL Compound: AZT	compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells	[PMID: 9548818]
CCRF-CEM	EC₅₀	0.003 μM Compound: n AZT	Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells	[PMID: 11714616]
CCRF-CEM	EC₅₀	0.004 μM Compound: n AZT	Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells	[PMID: 11714616]
CCRF-CEM	EC₅₀	0.005 μM Compound: 3 (AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.006 μM Compound: AZT	Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%. Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.	[PMID: 11356105]
CCRF-CEM	EC₅₀	0.0064 μM Compound: AZT	Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%. Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.	[PMID: 11356105]
CCRF-CEM	EC₅₀	0.008 μM Compound: 3 (AZT)	Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells. Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.	10.1016/0960-894X(96)00195-3
CCRF-CEM	EC₅₀	0.012 μM Compound: 4, AZT	Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	0.067 μM Compound: 4, AZT	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	ED₅₀	0.12 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.	[PMID: 1712047]
CCRF-CEM	ED₅₀	0.12 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.	[PMID: 1712047]
CCRF-CEM	ED₅₀	0.18 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.	[PMID: 1712047]
CCRF-CEM	ED₅₀	0.45 μM Compound: AZT	Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22. Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.	[PMID: 1712047]
CCRF-CEM	EC₅₀	0.7 μM Compound: AZT	Cytotoxicity against african human CEM cells after 6 days by XTT assay Cytotoxicity against african human CEM cells after 6 days by XTT assay	[PMID: 20691339]
CCRF-CEM	IC₅₀	1.04 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA	[PMID: 20350812]
CCRF-CEM	EC₅₀	1.05 μM Compound: AZT	Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA	[PMID: 21295891]
CCRF-CEM	IC₅₀	1.05 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry	[PMID: 20137956]
CCRF-CEM	EC₅₀	1.1 μM Compound: AZT	Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA	[PMID: 21227704]
CCRF-CEM	IC₅₀	13 μM Compound: AZT	Compound was evaluated for its toxicity by Calorimetric assay in CEM Compound was evaluated for its toxicity by Calorimetric assay in CEM	[PMID: 9357530]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 3 days by MTT assay Cytotoxicity against human CEM cells after 3 days by MTT assay	[PMID: 19153047]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay	[PMID: 21700368]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 25701249]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 5 days Cytotoxicity against human CEM cells after 5 days	[PMID: 19948402]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method	[PMID: 22014549]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against human CEM cells after 6 days Cytotoxicity against human CEM cells after 6 days	[PMID: 17158051]
CCRF-CEM	IC₅₀	14.3 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay	10.1007/s00044-011-9912-x
CCRF-CEM	IC₅₀	191 μM Compound: AZT	Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration	[PMID: 8627600]
CCRF-CEM	CC₅₀	23.04 μM Compound: AZT	Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay	[PMID: 20598537]
CCRF-CEM	CC₅₀	24 μM Compound: AZT	Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay	[PMID: 20350812]
CCRF-CEM	CC₅₀	24.06 μM Compound: AZT	Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay	[PMID: 21295891]
CCRF-CEM	CC₅₀	24.06 μM Compound: AZT	Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay	[PMID: 20137956]
CCRF-CEM	CC₅₀	24.1 μM Compound: AZT	Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay	[PMID: 21227704]
CCRF-CEM	CC₅₀	35.6 μg/mL Compound: AZT	compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells	[PMID: 9548818]
CCRF-CEM	IC₅₀	35.6 μM Compound: AZT	Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay	[PMID: 20691339]
CCRF-CEM	IC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human CEM cells after 5 days by trypan blue assay Cytotoxicity against human CEM cells after 5 days by trypan blue assay	[PMID: 21371895]
CCRF-CEM	CC₅₀	56.1 μM Compound: AZT	Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay	[PMID: 26451771]
CCRF-CEM	CC₅₀	6 μM Compound: n AZT	Concentration required to reduce the viability of mock-infected CEM cells by 50% Concentration required to reduce the viability of mock-infected CEM cells by 50%	[PMID: 11714616]
CCRF-CEM	IC₅₀	7.7 μM Compound: AZT	Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay	[PMID: 22549138]
CCRF-CEM	CC₅₀	86.2 μM Compound: AZT	Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay	[PMID: 19596885]
CEM-c113	CC₅₀	> 5 μM Compound: AZT	Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells	[PMID: 9154976]
CEM-c113	EC₅₀	0.006 μM Compound: AZT	Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay. Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.	[PMID: 8385224]
CEM-SS	IC₅₀	> 0.1 μM Compound: AZT	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	[PMID: 20086149]
CEM-SS	CC₅₀	> 1 μM Compound: AZT, 3'-azidothymidine	Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay	[PMID: 24102161]
CEM-SS	CC₅₀	> 1 μM Compound: AZT	Cytotoxicity against human CEM-SS cells by MTT assay Cytotoxicity against human CEM-SS cells by MTT assay	[PMID: 20112915]
CEM-SS	CC₅₀	> 1 μM Compound: AZT	Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay	[PMID: 21035347]
CEM-SS	CC₅₀	> 1 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%. Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.	[PMID: 9240351]
CEM-SS	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human CEM-SS cells by MTT assay Cytotoxicity against human CEM-SS cells by MTT assay	[PMID: 19944610]
CEM-SS	CC₅₀	> 100 μM Compound: AZT	Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50% Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%	[PMID: 7562927]
CEM-SS	CC₅₀	> 100 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells	[PMID: 12593658]
CEM-SS	CC₅₀	> 100 μM Compound: 1, AZT	Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50% Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%	[PMID: 10821705]
CEM-SS	CC₅₀	> 1000 μM Compound: AZT	Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
CEM-SS	IC₅₀	0.002 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	EC₅₀	0.002 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 27234889]
CEM-SS	IC₅₀	0.0024 μM Compound: AZT	Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay	[PMID: 20112915]
CEM-SS	IC₅₀	0.0026 μM Compound: Zidovudine (AZT)	Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells	[PMID: 9548815]
CEM-SS	IC₅₀	0.003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	IC₅₀	0.003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	EC₅₀	0.003 μM Compound: AZT	Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells	[PMID: 12593658]
CEM-SS	IC₅₀	0.0031 μM Compound: Zidovudine (AZT)	Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells	[PMID: 9548815]
CEM-SS	EC₅₀	0.004 μM Compound: AZT	Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay	[PMID: 7932526]
CEM-SS	IC₅₀	0.004 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.0051 μM Compound: AZT	Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay	[PMID: 19944610]
CEM-SS	EC₅₀	0.0053 μM Compound: AZT, 3'-azidothymidine	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay	[PMID: 24102161]
CEM-SS	IC₅₀	0.006 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
CEM-SS	EC₅₀	0.006 μM Compound: AZT	Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined	[PMID: 7562927]
CEM-SS	IC₅₀	0.007 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	EC₅₀	0.009 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay	[PMID: 20086159]
CEM-SS	IC₅₀	0.01 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.015 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	EC₅₀	0.02 μM Compound: AZT	Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells	10.1016/0960-894X(95)00260-Z
CEM-SS	IC₅₀	0.028 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	IC₅₀	0.04 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat	[PMID: 20086149]
CEM-SS	IC₅₀	0.08 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
CEM-SS	EC₅₀	0.095 μM Compound: AZT	Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay	[PMID: 7932526]
CEM-SS	EC₅₀	0.3 μM Compound: AZT	Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells	10.1016/0960-894X(95)00260-Z
CEM-SS	EC₅₀	2 nM Compound: 2, AZT	Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay	[PMID: 22858097]
CEM-SS	IC₅₀	5.6 μM Compound: AZT	In vitro inhibition of CEM-SS cell growth by 50 % In vitro inhibition of CEM-SS cell growth by 50 %	[PMID: 2016713]
CEM-TK(-)	EC₅₀	> 100 μM Compound: AZT	Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50% Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%	[PMID: 11356105]
CEM-TK(-)	CC₅₀	> 1000 μM Compound: AZT	Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
CEM-TK(-)	CC₅₀	> 200 μg/mL Compound: AZT	Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%. Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.	[PMID: 9046339]
CEM-TK(+)	EC₅₀	> 100 μM Compound: AZT	Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined	[PMID: 7562927]
CEM-TK(+)	CC₅₀	> 100 μM Compound: AZT	Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50% Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%	[PMID: 7562927]
DU-145	IC₅₀	34.45 μM Compound: 13, AZT	Cytotoxicity against human DU145 cells after 48 hrs by SRB method Cytotoxicity against human DU145 cells after 48 hrs by SRB method	[PMID: 25933593]
H9	IC₅₀	< 0.0003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	< 0.0003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	< 0.0003 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	> 0.1 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	> 0.1 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	IC₅₀	> 0.1 μM Compound: AZT	Cytotoxicity against human H9 cells by MTS assay Cytotoxicity against human H9 cells by MTS assay	[PMID: 20086149]
H9	IC₅₀	0.001 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA	[PMID: 20086149]
H9	EC₅₀	0.001 μM Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.001 μM Compound: AZT	Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique	[PMID: 11430019]
H9	EC₅₀	0.002 μg/mL Compound: AZT	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 8946749]
H9	IC₅₀	0.002 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	EC₅₀	0.00289 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA	[PMID: 11678650]
H9	EC₅₀	0.009 μM Compound: AZT	Evaluation for anti-HIV activity using T cell line (H9). Evaluation for anti-HIV activity using T cell line (H9).	10.1016/S0960-894X(97)10108-1
H9	EC₅₀	0.01 μM Compound: AZT	Cytotoxicity against human H9 cells after 6 days by MTT assay Cytotoxicity against human H9 cells after 6 days by MTT assay	[PMID: 20846868]
H9	EC₅₀	0.012 μg/mL Compound: AZT	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 9748372]
H9	EC₅₀	0.012 μg/mL Compound: AZT	Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50% Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%	[PMID: 10021911]
H9	EC₅₀	0.015 μM Compound: AZT	Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%. Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.	[PMID: 9804704]
H9	EC₅₀	0.023 μM Compound: AZT	Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA	[PMID: 17190445]
H9	IC₅₀	0.027 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay	[PMID: 20086149]
H9	IC₅₀	0.03 μM Compound: AZT	In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent	[PMID: 1573638]
H9	EC₅₀	0.037 μM Compound: AZT	Anti-HIV activity was measured in H9-cells by MAGI assay Anti-HIV activity was measured in H9-cells by MAGI assay	[PMID: 9804704]
H9	ED₅₀	0.04 μg/mL Compound: AZT	Effective dose required to inhibit virus replication growth by 50% Effective dose required to inhibit virus replication growth by 50%	[PMID: 8642556]
H9	EC₅₀	0.04 μM Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8176401]
H9	EC₅₀	0.04 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	EC₅₀	0.04 μM Compound: AZT	Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined	10.1016/S0960-894X(01)81071-4
H9	EC₅₀	0.044 μM Compound: AZT	Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA	[PMID: 20187635]
H9	EC₅₀	0.045 M Compound: AZT	Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes	[PMID: 15149703]
H9	EC₅₀	0.045 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA	[PMID: 9917290]
H9	EC₅₀	0.045 μM Compound: AZT	Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50% Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%	10.1016/S0960-894X(97)10050-6
H9	EC₅₀	0.045 μM Compound: AZT	Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50% Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%	[PMID: 9873374]
H9	EC₅₀	0.052 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay	[PMID: 20527972]
H9	IC₅₀	1870 μM Compound: AZT	Cytotoxicity against human H9 cells after 4 days Cytotoxicity against human H9 cells after 4 days	[PMID: 17190445]
H9	IC₅₀	1871 μM Compound: AZT	Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days	[PMID: 11141100]
H9	IC₅₀	1872 μM Compound: AZT	Concentration required to inhibit uninfected H9 cell growth by 50% Concentration required to inhibit uninfected H9 cell growth by 50%	[PMID: 14736256]
H9	CC₅₀	1873 μM Compound: AZT	Cytotoxicity against human H9 cells after 6 days by XTT assay Cytotoxicity against human H9 cells after 6 days by XTT assay	[PMID: 20527972]
H9	IC₅₀	1875 μM Compound: AZT	Inhibitory activity against gorwth of uninfected H9 cell growth by 50% Inhibitory activity against gorwth of uninfected H9 cell growth by 50%	10.1016/S0960-894X(97)10050-6
H9	IC₅₀	1875 μM Compound: AZT	Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50% Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%	[PMID: 9873504]
H9	IC₅₀	1875 μM Compound: AZT	Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50% Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%	[PMID: 9873374]
H9	IC₅₀	1875 μM Compound: AZT	Concentration required to inhibit uninfected H9 cell growth by 50% Concentration required to inhibit uninfected H9 cell growth by 50%	[PMID: 15149703]
H9	IC₅₀	1875 μM Compound: AZT	Inhibitory concentration required to inhibit uninfected H9 cell growth by 50% Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%	[PMID: 11527717]
H9	IC₅₀	2000 μg/mL Compound: AZT	Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50% Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%	[PMID: 8642556]
H9	IC₅₀	2000 μM Compound: AZT	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8176401]
H9	IC₅₀	2000 μM Compound: AZT	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9	IC₅₀	2000 μM Compound: AZT	Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined	10.1016/S0960-894X(01)81071-4
H9	IC₅₀	50 nM Compound: AZT	Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay	10.1016/0960-894X(95)00306-E
H9	IC₅₀	500 μg/mL Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 8946749]
H9	IC₅₀	500 μg/mL Compound: AZT	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
H9	IC₅₀	500 μg/mL Compound: AZT	Concentration that inhibits uninfected H9 cell growth by 50%. Concentration that inhibits uninfected H9 cell growth by 50%.	[PMID: 12729671]
H9	IC₅₀	500 μg/mL Compound: AZT	Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50% Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%	[PMID: 10021911]
H9	IC₅₀	500 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay	[PMID: 20846868]
HEK-293T	CC₅₀	> 10 μM Compound: AZT	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEK-293T	EC₅₀	200 nM Compound: AZT	Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	[PMID: 22148316]
HEK-293T	EC₅₀	6 nM Compound: AZT	Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	[PMID: 22148316]
HeLa	IC₅₀	> 100 μM Compound: AZT, Zidovudine	Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay	[PMID: 17416522]
HeLa	IC₅₀	> 100 μM Compound: AZT, Zidovudine	Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay	[PMID: 17416522]
HeLa	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22858300]
HeLa	CC₅₀	> 25 μM Compound: Zidovudine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
HeLa	CC₅₀	> 270 μM Compound: AZT	Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay	[PMID: 19596885]
HeLa	EC₅₀	> 374 μM Compound: 2, AZT, Zidovudine	Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay	[PMID: 22352809]
HeLa	EC₅₀	0.002 μM Compound: AZT	Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay	[PMID: 11087576]
HeLa	EC₅₀	0.009 μM Compound: AZT	Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes	[PMID: 9258355]
HeLa	EC₅₀	0.013 μM Compound: AZT	Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes	[PMID: 9258355]
HeLa	IC₅₀	0.04 μM Compound: AZT	Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry	[PMID: 22858300]
HeLa	IC₅₀	10.77 μM Compound: 3; AZT	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HeLa	IC₅₀	10.77 μM Compound: AZT	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HeLa	EC₅₀	10.8 μM Compound: 2, AZT, Zidovudine	Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	[PMID: 22352809]
HeLa	EC₅₀	14.2 μM Compound: 2, AZT, Zidovudine	Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay	[PMID: 22352809]
HeLa	EC₅₀	2.9 μM Compound: AZT	Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes	[PMID: 9258355]
HeLa	IC₅₀	65.46 μM Compound: 13, AZT	Cytotoxicity against human HeLa cells after 48 hrs by SRB method Cytotoxicity against human HeLa cells after 48 hrs by SRB method	[PMID: 25933593]
HepG2	IC₅₀	> 400 μM Compound: Azidothymidine	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	> 479 μM Compound: AZT; Zidovudine	Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay	[PMID: 27342752]
HepG2	IC₅₀	13.03 μM Compound: 3; AZT	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HL-60	IC₅₀	96 μM Compound: AZT	Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay. Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.	[PMID: 1695683]
HOS	IC₅₀	1.4 μM Compound: AZT	Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
HOS	IC₅₀	20.1 μM Compound: AZT	Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
HOS	IC₅₀	3.6 μM Compound: AZT	Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
HOS	IC₅₀	39.6 μM Compound: AZT	Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	[PMID: 19678643]
Huh-7	EC₅₀	> 10 μM Compound: AZT	Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR	[PMID: 22014549]
Huh-7	CC₅₀	> 10 μM Compound: AZT	Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis	[PMID: 23623492]
Huh-7	CC₅₀	> 10 μM Compound: AZT	Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs	[PMID: 22014549]
JM1	CC₅₀	> 1000 μM Compound: AZT	Concentration required to reduce cell viability of JM cells by 50% Concentration required to reduce cell viability of JM cells by 50%	10.1016/0960-894X(96)00443-X
Jurkat	EC₅₀	0.09 μM Compound: AZT	Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis	[PMID: 22954898]
Jurkat	IC₅₀	120 nM Compound: AZT	Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay	[PMID: 21414776]
KB	IC₅₀	> 400 μM Compound: Azidothymidine	Antiproliferative activity against human KB cells by MTT assay Antiproliferative activity against human KB cells by MTT assay	[PMID: 31546197]
KB	IC₅₀	3.12 μg/mL Compound: AZT, Zidovudine	Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
KB	IC₅₀	9.77 μM Compound: 3; AZT	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KB	IC₅₀	9.77 μM Compound: AZT	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB 3-1	IC₅₀	9.17 μM Compound: AZT, Zidovudine	Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay	[PMID: 25440502]
M	EC₅₀	0.015 μM Compound: AZT	Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay	[PMID: 7932526]
MCF7	IC₅₀	13.74 μM Compound: AZT, Zidovudine	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25440502]
MCF7	IC₅₀	2.6 μg/mL Compound: AZT, Zidovudine	Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
MCF7	IC₅₀	34.97 μM Compound: 13, AZT	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 25933593]
MCF7	IC₅₀	7.67 μM Compound: AZT	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MOLT-3	CC₅₀	12.1 μM Compound: AZT	Cytotoxicity against human MOLT3 cells by MTS assay Cytotoxicity against human MOLT3 cells by MTS assay	[PMID: 22549138]
MOLT-3	CC₅₀	3.24 μg/mL Compound: AZT	Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay	[PMID: 21334901]
MOLT-4	EC₅₀	> 10 μM Compound: AZT	Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay	[PMID: 18316521]
MT2	CC₅₀	> 200 μM Compound: AZT	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20542430]
MT2	CC₅₀	> 200 μM Compound: AZT, zidovudine	Cytotoxicity against human MT2 cells after 5 days Cytotoxicity against human MT2 cells after 5 days	[PMID: 19179082]
MT2	CC₅₀	≥ 25 μM Compound: AZT	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 23570720]
MT2	EC₅₀	0.0012 μM Compound: AZT	Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0029 μM Compound: AZT	Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.003 μM Compound: AZT	Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay	[PMID: 7932526]
MT2	EC₅₀	0.0038 μM Compound: AZT	Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0049 μM Compound: AZT	Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0063 μM Compound: AZT	Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.014 μM Compound: AZT	Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.016 μM Compound: AZT	Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay	[PMID: 18316521]
MT2	EC₅₀	0.018 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.02 μM Compound: AZT	Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay	[PMID: 17004726]
MT2	EC₅₀	0.027 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.034 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA	[PMID: 20329730]
MT2	EC₅₀	0.038 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.043 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.044 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA	[PMID: 20537902]
MT2	IC₅₀	0.047 μM Compound: AZT	Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 20542430]
MT2	IC₅₀	0.0493 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	[PMID: 20728351]
MT2	EC₅₀	0.051 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.054 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.056 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA	[PMID: 19388685]
MT2	ED₅₀	0.07 μM Compound: AZT	Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia	[PMID: 7512142]
MT2	EC₅₀	0.075 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.087 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.117 μM Compound: AZT	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.144 μM Compound: AZT	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.16 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay	[PMID: 19179082]
MT2	EC₅₀	0.16 μM Compound: 3	Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days	[PMID: 17562366]
MT2	IC₅₀	0.16 μM Compound: AZT	In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	IC₅₀	0.2 μM Compound: AZT	In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	EC₅₀	0.209 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	IC₅₀	0.22 μM Compound: AZT	In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	EC₅₀	0.223 μM Compound: AZT	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.249 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.302 μM Compound: AZT	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	IC₅₀	10 μM Compound: AZT	In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	CC₅₀	150 μM Compound: AZT	Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay	[PMID: 19596885]
MT2	IC₅₀	1870 μM Compound: AZT	Cytotoxicity against human MT2 cells by XTT assay Cytotoxicity against human MT2 cells by XTT assay	[PMID: 20329730]
MT2	CC₅₀	1870 μM Compound: AZT	Cytotoxicity against human MT2 cells by XTT assay Cytotoxicity against human MT2 cells by XTT assay	[PMID: 19388685]
MT2	IC₅₀	1870 μM Compound: AZT	Cytotoxicity against MT2 cells by XTT assay Cytotoxicity against MT2 cells by XTT assay	[PMID: 17935987]
MT2	IC₅₀	1872 μM Compound: AZT	Cytotoxicity against human MT2 cells after 6 days by XTT assay Cytotoxicity against human MT2 cells after 6 days by XTT assay	[PMID: 20537902]
MT2	IC₅₀	31 μM Compound: AZT	In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent	[PMID: 1573638]
MT2	EC₅₀	47 nM Compound: AZT	Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay	[PMID: 21745701]
MT4	CC₅₀	> 0.00748 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 28481112]
MT4	CC₅₀	> 0.1 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay	[PMID: 26756779]
MT4	CC₅₀	> 0.37 μM Compound: AZT	Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay	[PMID: 33214842]
MT4	CC₅₀	> 0.37 μM Compound: AZT	Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay	[PMID: 31184480]
MT4	CC₅₀	> 0.4 μM Compound: AZT	Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay	[PMID: 30031972]
MT4	CC₅₀	> 0.5 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay	[PMID: 28682067]
MT4	CC₅₀	> 1 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	CC₅₀	> 1 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 20112915]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 23916148]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22277590]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 26094944]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19944610]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 17548498]
MT4	CC₅₀	> 100 μM Compound: AZT	Tested in vitro against MT-4 cells using MTT assay Tested in vitro against MT-4 cells using MTT assay	[PMID: 11087576]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine	[PMID: 26094944]
MT4	CC₅₀	> 100 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells	[PMID: 12593658]
MT4	CC₅₀	> 100 μM Compound: 1, AZT	Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50% Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%	[PMID: 10821705]
MT4	CC₅₀	> 15 μM Compound: AZT	Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31860304]
MT4	CC₅₀	> 15 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	> 18710 nM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	[PMID: 22712652]
MT4	CC₅₀	> 2 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 34583311]
MT4	CC₅₀	> 2.5 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	CC₅₀	> 20 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(97)00340-5
MT4	CC₅₀	> 20 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 8558522]
MT4	CC₅₀	> 20 μM Compound: AZT	Compound dose required to reduce the viability of mock-infected cells by 50% Compound dose required to reduce the viability of mock-infected cells by 50%	[PMID: 7650679]
MT4	CC₅₀	> 2000 nM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 29353724]
MT4	CC₅₀	> 25 μg/mL Compound: Azidothymidine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay	[PMID: 26707844]
MT4	CC₅₀	> 25 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	CC₅₀	> 25 μg/mL Compound: Zidovudine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	CC₅₀	> 25 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27647368]
MT4	CC₅₀	> 25 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	CC₅₀	> 25 μg/mL Compound: DDN, AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	CC₅₀	> 25 μM Compound: azidothymidine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	CC₅₀	> 25 μM Compound: azidothymidine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	> 3.74 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by cytoTox-Glo reagent based assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by cytoTox-Glo reagent based assay	[PMID: 30010341]
MT4	CC₅₀	> 30595 nM Compound: AZT	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 32883642]
MT4	CC₅₀	> 30595 nM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 28628334]
MT4	CC₅₀	> 30595 nM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24769348]
MT4	CC₅₀	> 37 μM Compound: AZT	Cytotoxicity against human MT4 cells after 2 days Cytotoxicity against human MT4 cells after 2 days	[PMID: 22978745]
MT4	IC₅₀	> 37.4 μM Compound: AZT	Cytotoxicity against human MT4 cells after 4 days Cytotoxicity against human MT4 cells after 4 days	[PMID: 20673723]
MT4	CC₅₀	> 50 μM Compound: AZT	Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 32305183]
MT4	CC₅₀	> 7 μM Compound: Azidothymidine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 28314598]
MT4	CC₅₀	> 7.48 μM Compound: AZT; zidovudine	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	[PMID: 34090079]
MT4	CC₅₀	> 7.48 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 33979774]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in mock-infected human MT4 assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32631509]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29635166]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29559197]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 28254696]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 26613134]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	[PMID: 35640327]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 29670703]
MT4	CC₅₀	> 7.48 μM Compound: AZT	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 28987601]
MT4	CC₅₀	> 7.484 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29152052]
MT4	CC₅₀	> 7.49 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	CC₅₀	> 7.5 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 33340914]
MT4	CC₅₀	> 7480 nM Compound: AZT	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	CC₅₀	> 80 μM Compound: AZT	Dose required to reduce the viability of mock-infected cells by 50% Dose required to reduce the viability of mock-infected cells by 50%	[PMID: 9154967]
MT4	CC₅₀	> 80 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days) Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days)	[PMID: 7523675]
MT4	CC₅₀	> 88.26 μM Compound: AZT, azidothymidine	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	> 93.5 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	CC₅₀	> 93.5 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	CC₅₀	> 93.5489 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24952305]
MT4	CC₅₀	> 93.55 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	CC₅₀	> 93.55 μM Compound: AZT, azidothymidine	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	> 93.55 μM Compound: AZT, Azidothymidine	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	[PMID: 24602795]
MT4	CC₅₀	> 93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 23707918]
MT4	CC₅₀	> 93.55 μM Compound: AZT, azidothymidine	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	[PMID: 21683601]
MT4	CC₅₀	> 93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	[PMID: 19628308]
MT4	CC₅₀	> 93.55 μM Compound: AZT, azidothymidine	Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay	10.1007/s00044-009-9220-x
MT4	CC₅₀	> 93.55 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay	[PMID: 23099090]
MT4	CC₅₀	> 93.55 μM Compound: azidothymidine,AZT	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19643613]
MT4	CC₅₀	> 93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	CC₅₀	> 93.56 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	CC₅₀	> 93.6 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24680058]
MT4	CC₅₀	> 93.63 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 23159806]
MT4	CC₅₀	> 93550 nM Compound: AZT	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	> 94 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	> 94 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	CC₅₀	> 94 μM Compound: AZT	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25907370]
MT4	CC₅₀	> 94 μM Compound: AZT, Zidovudine	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24275349]
MT4	CC₅₀	> 99 μM Compound: Azidothymidine	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	CC₅₀	≥ 3.74 μM Compound: AZT	Cytotoxicity against human MT4 cells by cellTiterGlo assay Cytotoxicity against human MT4 cells by cellTiterGlo assay	[PMID: 26562066]
MT4	CC₅₀	≥ 46 μM Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	≥ 46.44 μM Compound: Zidovudine	Cytotoxicity against human MT4 cells measured by MTT assay Cytotoxicity against human MT4 cells measured by MTT assay	[PMID: 22037050]
MT4	CC₅₀	≥ 49.77 μM Compound: AZT, Azidothymidine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	≥ 50 μM Compound: AZT, azidothymidine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 22883027]
MT4	IC₅₀	0.0002 μg/mL Compound: zidovudine	Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 10425115]
MT4	EC₅₀	0.0007 μM Compound: AZT, zidovudine	Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	EC₅₀	0.0007 μM Compound: AZT	Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method. Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.	[PMID: 9767646]
MT4	EC₅₀	0.0008 μg/mL Compound: AZT	Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	EC₅₀	0.0009 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	0.0009 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	IC₅₀	0.00094 μg/mL Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	0.00094 μg/mL Compound: DDN, AZT	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	0.00094 μg/mL Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.001 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	0.0012 μg/mL Compound: AZT	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21515046]
MT4	EC₅₀	0.0015 μg/mL Compound: AZT	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	EC₅₀	0.0016 μM Compound: Zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	IC₅₀	0.0017 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	EC₅₀	0.0019 μM Compound: Zidovudine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	IC₅₀	0.002 μg/mL Compound: Zidovudine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	IC₅₀	0.0022 μg/mL Compound: AZT	Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	0.0022 μg/mL Compound: DDN, AZT	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	0.0022 μg/mL Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.003 μM Compound: AZT	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.0032 μg/mL Compound: AZT	In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay	10.1016/0960-894X(95)00395-A
MT4	EC₅₀	0.0033 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.004 μM Compound: AZT, azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.004 μM Compound: AZT, azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.004 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	EC₅₀	0.004 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay	[PMID: 26756779]
MT4	EC₅₀	0.004 μM Compound: AZT	Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50% Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50%	[PMID: 2016718]
MT4	EC₅₀	0.004 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.0045 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.0045 μM Compound: AZT	AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay	[PMID: 1695683]
MT4	EC₅₀	0.0048 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0049 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	IC₅₀	0.005 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	EC₅₀	0.005 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.005 μM Compound: Zidovudine	Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.005 μM Compound: AZT	Antiviral activity against HIV1 3B infected in MT4 cells by MTT Antiviral activity against HIV1 3B infected in MT4 cells by MTT	[PMID: 18267363]
MT4	EC₅₀	0.005 μM Compound: AZT	Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa) Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa)	[PMID: 10212126]
MT4	EC₅₀	0.005 μM Compound: AZT	Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD) Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD)	[PMID: 10212126]
MT4	EC₅₀	0.0052 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0052 μM Compound: AZT	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.0056 μM Compound: AZT	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.0057 μM Compound: AZT, Zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0059 μM Compound: AZT	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.006 μM Compound: Zidovudine	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.006 μM Compound: Zidovudine	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	IC₅₀	0.006 μM Compound: azidothymidine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.006 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.006 μM Compound: azidothymidine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.006 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.006 μM Compound: Zidovudine	Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.006 μM Compound: AZT	Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT	[PMID: 18267363]
MT4	EC₅₀	0.006 μM Compound: AZT	AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA). AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).	[PMID: 1695683]
MT4	EC₅₀	0.0063 μM Compound: AZT	Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.0064 μM Compound: AZT	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.0064 μM Compound: AZT	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.0066 μM Compound: AZT	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	IC₅₀	0.0066 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	EC₅₀	0.0066 μM Compound: AZT	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.0067 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0067 μM Compound: AZT, azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.007 μg/mL Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	0.007 μM Compound: AZT; zidovudine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.007 μM Compound: Zidovudine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.007 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.007 μM Compound: AZT	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.007 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	0.007 μM Compound: Zidovudine	Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.007 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.0071 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0071 μM Compound: AZT	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.0071 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	IC₅₀	0.0071 μM Compound: azidothymidine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	EC₅₀	0.0071 μM Compound: azidothymidine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	0.0072 μM Compound: AZT, Zidovudine	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0074 μM Compound: AZT, Zidovudine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0075 μM Compound: AZT, Azidothymidine	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.0075 μM Compound: Zidovudine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.0075 μM Compound: Zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.0076 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	IC₅₀	0.0077 μM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.008 μM Compound: Azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.008 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.0082 μM Compound: AZT; zidovudine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.0083 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0086 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	0.009 μM Compound: AZT	Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method	[PMID: 19254848]
MT4	EC₅₀	0.009 μM Compound: AZT	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.009 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay	10.1007/s00044-012-0342-1
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	10.1007/s00044-010-9513-0
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.01 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	0.01 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	IC₅₀	0.01 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay	[PMID: 19944610]
MT4	EC₅₀	0.011 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.011 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.011 μM Compound: AZT	Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.012 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.013 μM Compound: Zidovudine	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.013 μM Compound: AZT	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.015 μM Compound: AZT, azidothymidine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 21683601]
MT4	EC₅₀	0.015 μM Compound: AZT	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.015 μM Compound: AZT	Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells	[PMID: 12593658]
MT4	EC₅₀	0.0151 μM Compound: AZT, azidothymidine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay	10.1007/s00044-009-9220-x
MT4	EC₅₀	0.0151 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	[PMID: 19628308]
MT4	EC₅₀	0.0151 μM Compound: azidothymidine,AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 19643613]
MT4	EC₅₀	0.016 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.016 μM Compound: AZT ; azidothymidine	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.017 μM Compound: AZT; zidovudine	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.017 μM Compound: AZT	Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined	[PMID: 7562927]
MT4	EC₅₀	0.018 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.018 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	IC₅₀	0.018 μM Compound: AZT	Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay	[PMID: 20112915]
MT4	EC₅₀	0.018 μM Compound: Zidovudine	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22277590]
MT4	EC₅₀	0.02 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.02 μM Compound: AZT	Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.02 μM Compound: 1, AZT	Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay	[PMID: 10821705]
MT4	EC₅₀	0.021 μM Compound: AZT, Azidothymidine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.021 μM Compound: AZT, azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.021 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.022 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.022 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.022 μM Compound: Zidovudine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.026 μM Compound: AZT	Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.027 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.027 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay	[PMID: 20673723]
MT4	IC₅₀	0.03 μM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA	[PMID: 22978745]
MT4	EC₅₀	0.032 μM Compound: AZT	Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed as viral replication measured on day 4 post infection by ELISA Antiviral activity against HIV-1 NL4-3 infected in MT4 cells assessed as viral replication measured on day 4 post infection by ELISA	[PMID: 26562066]
MT4	EC₅₀	0.033 μM Compound: AZT	Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay	[PMID: 17548498]
MT4	EC₅₀	0.035 μM Compound: AZT	Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells	10.1016/0960-894X(95)00208-B
MT4	EC₅₀	0.038 μM Compound: AZT	Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay	[PMID: 11087576]
MT4	EC₅₀	0.04 μM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay	[PMID: 23916148]
MT4	IC₅₀	0.05 μM Compound: AZT	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay	[PMID: 18212100]
MT4	EC₅₀	0.05 μM Compound: AZT	Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells	[PMID: 9925728]
MT4	EC₅₀	0.056 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	ED₅₀	0.06 μM Compound: AZT	Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50% Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50%	10.1016/S0960-894X(01)80332-2
MT4	EC₅₀	0.067 μM Compound: AZT	Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.085 μM Compound: AZT	Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay	[PMID: 7932526]
MT4	EC₅₀	0.1 μM Compound: AZT	Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	EC₅₀	0.12 μM Compound: AZT	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26094944]
MT4	EC₅₀	0.2 μM Compound: AZT	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.2 μM Compound: AZT	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.2 μM Compound: AZT	Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.3 μM Compound: AZT	Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method	[PMID: 11958995]
MT4	EC₅₀	0.6 μM Compound: AZT	Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19282192]
MT4	CC₅₀	1.5 μg/mL Compound: AZT	Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%. Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%.	[PMID: 9046339]
MT4	EC₅₀	1.6 nM Compound: AZT	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	CC₅₀	1.9 μg/mL Compound: AZT	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 12444692]
MT4	EC₅₀	10 nM Compound: AZT	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	IC₅₀	100 μM Compound: AZT	Concentration of compound required to reduce MT-4 cell viability by 50% Concentration of compound required to reduce MT-4 cell viability by 50%	[PMID: 10212126]
MT4	EC₅₀	11.7 nM Compound: AZT	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	12 nM Compound: AZT	Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent) Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent)	[PMID: 11881996]
MT4	EC₅₀	12 nM Compound: AZT	Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells	[PMID: 11520210]
MT4	CC₅₀	12 μM Compound: AZT	Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method	[PMID: 11958995]
MT4	CC₅₀	140 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33711763]
MT4	EC₅₀	15.6 nM Compound: AZT	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	16 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	16 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	CC₅₀	2 μg/mL Compound: Zidovudine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	CC₅₀	2.01 μg/mL Compound: AZT	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 19091580]
MT4	CC₅₀	2.5813 μg/mL Compound: zidovudine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 10425115]
MT4	EC₅₀	20 μM Compound: AZT	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay	[PMID: 23375089]
MT4	CC₅₀	20 μM Compound: AZT	Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 2479745]
MT4	CC₅₀	20 μM Compound: AZT	Concentration of compound required to reduce MT-4 cells viability by 50%. Concentration of compound required to reduce MT-4 cells viability by 50%.	[PMID: 2016718]
MT4	CC₅₀	20 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 1992136]
MT4	EC₅₀	20.6 nM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	249 μM Compound: AZT, azidothymidine	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	249 μM Compound: AZT, azidothymidine	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	249 μM Compound: AZT, azidothymidine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23084898]
MT4	CC₅₀	249.5 μM Compound: AZT, Azidothymidine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	249.5 μM Compound: AZT, Azidothymidine	Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	249.5 μM Compound: AZT, Azidothymidine	Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	25 nM Compound: AZT	Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent) Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent)	[PMID: 11881996]
MT4	CC₅₀	27 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	3.7 nM Compound: AZT	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	CC₅₀	3.7 μM Compound: AZT	Cytotoxicity against MT4 cells by MTT assay Cytotoxicity against MT4 cells by MTT assay	[PMID: 16621553]
MT4	CC₅₀	3.7 μM Compound: AZT	Cytotoxicity against MT4 cells by MTT method Cytotoxicity against MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	3.8 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	3.8 nM Compound: AZT	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	CC₅₀	31 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	33 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	CC₅₀	35.6 μM Compound: AZT, zidovudine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	CC₅₀	35.6 μM Compound: AZT	Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method. Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.	[PMID: 9767646]
MT4	EC₅₀	4.8 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	4.8 μM Compound: AzddThd	Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50%	[PMID: 1697345]
MT4	EC₅₀	5.2 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5.8 nM Compound: AZT	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	50 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay	10.1007/s00044-012-0342-1
MT4	CC₅₀	50 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay	10.1007/s00044-010-9513-0
MT4	CC₅₀	50 μM Compound: AZT	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	IC₅₀	53 μM Compound: AZT	Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay. Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.	[PMID: 1695683]
MT4	IC₅₀	57.28 μg/mL Compound: 4	Concentration required to reduce the number of viable uninfected cells by 50% Concentration required to reduce the number of viable uninfected cells by 50%	[PMID: 7473592]
MT4	EC₅₀	6 nM Compound: AZT, Azidothymidine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	6 nM Compound: AZT	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	6 μM Compound: azidothymidine	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 25970561]
MT4	EC₅₀	6 μM Compound: AZT, azidothymidine	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	6.3 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	6.6 nM Compound: AZT	Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	6.7 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	IC₅₀	60 nM Compound: 1	Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay	[PMID: 1380561]
MT4	CC₅₀	60 μM Compound: AZT	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19282192]
MT4	CC₅₀	61 μM Compound: AZT	Cytotoxicity against human MT4 cells by MTS method Cytotoxicity against human MT4 cells by MTS method	[PMID: 19254848]
MT4	CC₅₀	65.4 μg/mL Compound: AZT	Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay	[PMID: 21515046]
MT4	CC₅₀	7.06 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35679690]
MT4	EC₅₀	7.1 nM Compound: AZT	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	7.1 μM Compound: azidothymidine	Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 25970561]
MT4	EC₅₀	7.3 nM Compound: AZT	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	7.5 μM Compound: Azidothymidine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28314514]
MT4	EC₅₀	7.8 nM Compound: AZT	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	CC₅₀	7.8 μM Compound: AZT	The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain	[PMID: 7636846]
MT4	CC₅₀	7.8 μM Compound: AZT	The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain	[PMID: 7636846]
MT4	CC₅₀	7.8 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	7.8 μM Compound: AZT	Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50% Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%	[PMID: 2016729]
MT4	CC₅₀	7.8 μM Compound: AZT	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1732552]
MT4	CC₅₀	74 μM Compound: AZT	Cytotoxicity against in human MT-4 after 5 days by MTT assay Cytotoxicity against in human MT-4 after 5 days by MTT assay	[PMID: 33316719]
MT4	CC₅₀	75 μM Compound: AZT	Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50% Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%	[PMID: 7562927]
MT4	CC₅₀	77.5 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo luminescent assay	[PMID: 30703659]
MT4	CC₅₀	9.3 μM Compound: AZT	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%. Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.	[PMID: 1995896]
MT4	CC₅₀	93.55 μM Compound: AZT	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20638854]
MT4	CC₅₀	93.56 μM Compound: AZT	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
NCI-H460	IC₅₀	6.81 μM Compound: AZT, Zidovudine	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 25440502]
NHDF	IC₅₀	14.41 μM Compound: 3; AZT	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
NHDF	IC₅₀	14.41 μM Compound: AZT	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NIH3T3	IC₅₀	> 200 μM Compound: 13, AZT	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method	[PMID: 25933593]
PBL	EC₅₀	0.029 μM Compound: AZT	Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay	[PMID: 7932526]
PBL	CC₅₀	12 μM Compound: AZT	The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain	[PMID: 7636846]
PBMC	CC₅₀	> 10 μM Compound: AZT	Cytotoxicity against human PHA-PBMC cells by MTT assay Cytotoxicity against human PHA-PBMC cells by MTT assay	[PMID: 17548498]
PBMC	CC₅₀	> 100 μM Compound: AZT, zidovudine	Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay	[PMID: 21376429]
PBMC	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC after 2 to 4 days by MTT assay Cytotoxicity against human PBMC after 2 to 4 days by MTT assay	[PMID: 19596885]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBM cells after 3 days by MTT assay Cytotoxicity against human PBM cells after 3 days by MTT assay	[PMID: 19153047]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC after 5 days by trypan blue assay Cytotoxicity against human PBMC after 5 days by trypan blue assay	[PMID: 21371895]
PBMC	IC₅₀	> 100 μM Compound: 27, L-AZT	Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay	[PMID: 21700368]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method	[PMID: 9322359]
PBMC	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay Cytotoxicity against human PBMC assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay	[PMID: 26451771]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 25701249]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC after 5 days Cytotoxicity against human PBMC after 5 days	[PMID: 19948402]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method	[PMID: 22014549]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human PBMC after 6 days Cytotoxicity against human PBMC after 6 days	[PMID: 17158051]
PBMC	IC₅₀	> 100 μM Compound: AZT	Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay	10.1007/s00044-011-9912-x
PBMC	IC₅₀	0.0002162 mM Compound: AZT	Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
PBMC	EC₅₀	0.0033 μM Compound: AZT	Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay	[PMID: 25701249]
PBMC	EC₅₀	0.008 μM Compound: AZT	Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.016 μM Compound: AZT	Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.018 μM Compound: AZT	Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.034 μM Compound: AZT	Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.05 μM Compound: AZT	Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA	[PMID: 19581097]
PBMC	IC₅₀	0.8291 mM Compound: AZT	Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA	10.1039/C4MD00003J
PBMC	IC₅₀	100 μM Compound: AZT	Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay	[PMID: 21700368]
PBMC	CC₅₀	1071 μM Compound: AZT	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31557609]
PBMC	CC₅₀	126 μM Compound: AZT	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by XTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by XTT assay	[PMID: 32244098]
PBMC	CC₅₀	126 μM Compound: AZT	Cytotoxicity against human PBMC by XTT assay Cytotoxicity against human PBMC by XTT assay	[PMID: 19581097]
PBMC	CC₅₀	128 μM Compound: AZT	Cytotoxicity against human PBMC after 7 days by XTT assay Cytotoxicity against human PBMC after 7 days by XTT assay	[PMID: 22763201]
PBMC	CC₅₀	31.2 μg/mL Compound: AZT	Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay	[PMID: 21334901]
PBMC	CC₅₀	75 μM Compound: AZT	Cytotoxicity against human PBMC by MTT assay Cytotoxicity against human PBMC by MTT assay	[PMID: 19944610]
SUP-T1	IC₅₀	50 nM Compound: AZT	Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay	10.1016/0960-894X(95)00306-E
SW-620	IC₅₀	39.11 μM Compound: AZT, Zidovudine	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 25440502]
T-cell line	CC₅₀	66000 nM Compound: Zidovudine (AZT)	In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay	[PMID: 1712395]
TZM	CC₅₀	> 0.374 μM Compound: AZT	Cytotoxicity in human TZM assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in human TZM assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32631509]
TZM	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 33157478]
TZM	CC₅₀	> 6300 nM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	[PMID: 33340914]
TZM	IC₅₀	0.8 nM Compound: AZT	Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy	[PMID: 22858300]
TZM	CC₅₀	872 μM Compound: AZT	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31557609]
U-87MG ATCC	IC₅₀	11.88 μM Compound: 3; AZT	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
U-937	EC₅₀	0.03 μM Compound: AZT	Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay	[PMID: 7932526]
Vero	CC₅₀	> 100 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay	[PMID: 19596885]
Vero	IC₅₀	> 100 μM Compound: 27, L-AZT	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry	[PMID: 21700368]
Vero	CC₅₀	126 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 18486994]
Vero	IC₅₀	29 μM Compound: AZT	Compound was evaluated for its toxicity by Calorimetric assay in vero cells Compound was evaluated for its toxicity by Calorimetric assay in vero cells	[PMID: 9357530]
Vero	CC₅₀	39.5 μM Compound: AZT	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay	[PMID: 26451771]
Vero	IC₅₀	50 μM Compound: AZT	Cytotoxicity against Vero cells after 3 days Cytotoxicity against Vero cells after 3 days	[PMID: 17158051]
Vero	IC₅₀	50.6 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	[PMID: 19153047]
Vero	IC₅₀	50.6 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry	[PMID: 21700368]
Vero	IC₅₀	50.6 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 5 days Cytotoxicity against african green monkey Vero cells after 5 days	[PMID: 19948402]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis	[PMID: 22014549]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay	[PMID: 25701249]
Vero	IC₅₀	56 μM Compound: AZT	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay	10.1007/s00044-011-9912-x
WI-38	CC₅₀	> 100 μM Compound: Azidothymidine	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	> 100 μM Compound: Azidothymidine	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

In Vitro

Zidovudine inhibits SVG, Primary human fetal astrocytes (PFA), peripheral blood mononuclear cells (PBMC), and monocyte-derived macrophages (MDM) with EC₅₀ of 17, 1311, 8, and 5 nM, respectively. Zidovudine inhibits SVG, PFA, PBMC, and MDM with EC₉₀ of 0.205 μM, 44.157 μM, 0.481 μM, and 0.219 μM, respectively^[1]. Genome editing via CRISPR/Cas9 has become an efficient and reliable way to make precise, targeted changes to the genome of living cells. CXCR4 is a co-receptor for the human immunodeficiency virus type 1 (HIV-1) infection and has been considered as an important therapeutic target for AIDS. CXCR4 mediates viral entry into human CD4⁺ cells by binding to envelope protein, gp120. Human CXCR4 gene is efficiently disrupted by CRISPR/Cas9-mediated genome editing, leading to HIV-1 resistance of human primary CD4⁺ T cells. The Cas9-mediated ablation of CXCR4 demonstrated high specificity and negligible off-target effects without affecting cell division and propagation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Intravitrous injection of the NRTIs Lamivudine (3TC), Zidovudine (AZT), or Abacavir (ABC) suppresses the laser-induced choroidal neovascularization (CNV) in wild-type mice compared to PBS vehicle. The mean level of VEGF-A in the RPE/choroid, which peaks on day 3 after laser injury, is significantly reduced in 3TC-, AZT- and ABC-treated eyes compared with control eyes in wild-type mice, but not inP2rx7^-/- mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

267.24

Formula

C₁₀H₁₃N₅O₄

CAS No.

30516-87-1

Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H]1[C@@H](N=[N+]=[N-])C[C@H](N2C(NC(C(C)=C2)=O)=O)O1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (374.20 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 16.67 mg/mL (62.38 mM; ultrasonic and warming and heat to 60°C)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7420 mL	18.7098 mL	37.4195 mL
5 mM	0.7484 mL	3.7420 mL	7.4839 mL
10 mM	0.3742 mL	1.8710 mL	3.7420 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 20 mg/mL (74.84 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (281 KB) SDS (418 KB)

COA (250 KB) HNMR (123 KB) RP-HPLC (243 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. [Content Brief]

[2]. Hou P, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015 Oct 20;5:15577. [Content Brief]

[3]. Mizutani T, et al. Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7122-9. [Content Brief]

Cell Assay ^[1]	Assays are performed in all cell types in the presence of titrating concentrations of ARV. 5,000 SVG, 2,500 PFA, 200,000 PBMC, or 50,000 MDM cells/well are seeded into triplicate wells of 96-well plates. Twenty-four hours later, the culture medium is removed and replaced with medium containing the ARV or DMSO (0.5% vol/vol), and equivalent TCID50 infectious units of luciferase reporter virus are added to the cells. After a 16 h incubation at 37°C, the initial viral inoculum is removed and replaced with culture medium containing the same antiretroviral drug (ARV) or DMSO (0.5% vol/vol) concentrations. At 72 h post infection, the medium is aspirated, the cells are lysed and HIV-1 infection measured using the Luciferase Assay System. Luminescence is measured using a FLUOStar Optima microplate reader. Inhibition curves and the 50% (EC₅₀) and 90% (EC₉₀) effective concentrations are determined by nonlinear regression analysis, using GraphPad Prism software^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] C57BL/6J (wild-type) and P2rx7^-/- mice are used. The Nlrp3^-/- mice are used. The NRTIs 3TC, AZT, and ABC or the P2X7 antagonist A438079 hydrochloride are dissolved in PBS. For CNV, each group of mice is injected once with 1 μL of NRTIs (3TC, 125 ng/μL; ABC, 183 ng/μL; AZT, 146 ng/μL), 1 μL of A438079 hydrochloride (3, 30, or 300 ng/μL), or the same volume of vehicle (PBS) into the vitreous humor using a 33-gauge needle immediately after laser injury. Another group of mice is injected with 3TC (125 ng) in combination with an anti-mouse VEGF polyclonal antibody (10 ng). Goat whole IgG (10 ng) is used as a biological control for the anti-mouse VEGF antibody. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. [Content Brief] [2]. Hou P, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015 Oct 20;5:15577. [Content Brief] [3]. Mizutani T, et al. Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7122-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.7420 mL	18.7098 mL	37.4195 mL	93.5489 mL
	5 mM	0.7484 mL	3.7420 mL	7.4839 mL	18.7098 mL
	10 mM	0.3742 mL	1.8710 mL	3.7420 mL	9.3549 mL
	15 mM	0.2495 mL	1.2473 mL	2.4946 mL	6.2366 mL
	20 mM	0.1871 mL	0.9355 mL	1.8710 mL	4.6774 mL
	25 mM	0.1497 mL	0.7484 mL	1.4968 mL	3.7420 mL
	30 mM	0.1247 mL	0.6237 mL	1.2473 mL	3.1183 mL
	40 mM	0.0935 mL	0.4677 mL	0.9355 mL	2.3387 mL
	50 mM	0.0748 mL	0.3742 mL	0.7484 mL	1.8710 mL
	60 mM	0.0624 mL	0.3118 mL	0.6237 mL	1.5591 mL
DMSO	80 mM	0.0468 mL	0.2339 mL	0.4677 mL	1.1694 mL
DMSO	100 mM	0.0374 mL	0.1871 mL	0.3742 mL	0.9355 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Zidovudine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zidovudine30516-87-1Azidothymidine AZT ZDVHIVCRISPR/Cas9Human immunodeficiency virusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Zidovudine (Synonyms: Azidothymidine; AZT; ZDV)

Customer Review

Other Forms of Zidovudine:

Zidovudine Related Antibodies

6 Publications Citing Use of MCE Zidovudine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Zidovudine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Zidovudine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report